# SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

> **NCT02437487** · PHASE2 · COMPLETED · sponsor: **Seres Therapeutics, Inc.** · enrollment: 89 (actual)

## Conditions studied

- Clostridium Difficile

## Interventions

- **DRUG:** SER-109
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02437487
- **Lead sponsor:** Seres Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2016-07
- **Final completion:** 2016-10
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2018-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02437487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02437487, "SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02437487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*